Richard Kendall

5.1k citations

43 papers · 3.0k indexed · 1 hit paper · h-index 24

Co-authors: Kenneth A. Thomas Guan Wang Robert Radinsky Xianzhi Mao Angela Coxon William R. Huckle Teresa L. Burgess Randall W. Hungate
Topics: Cancer, Hypoxia, and Metabolism (9 papers)Microtubule and mitosis dynamics (8 papers)Cancer Treatment and Pharmacology (8 papers)
Cited by: Hepatology Cancer Research Oncology
Journals: Science Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States Sweden Germany

In The Last Decade

Richard Kendall

42 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR

1996 597 citations Richard Kendall, Guan Wang et al. Biochemical and Biophysical Research Communications profile →

Peers

Countries citing papers authored by Richard Kendall

Since Specialization

Citations

This map shows the geographic impact of Richard Kendall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kendall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kendall more than expected).

Fields of papers citing papers by Richard Kendall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kendall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kendall. The network helps show where Richard Kendall may publish in the future.

Co-authorship network of co-authors of Richard Kendall

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Kendall. A scholar is included among the top collaborators of Richard Kendall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Kendall. Richard Kendall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 5797: Next generation antibody drug conjugates: Multi-payload conjugates targeting multiple mechanisms of cell killing 2024 ·Cancer Research ·Richard Kendall,Marco Lobba,(unknown),Chanez Symister,(unknown),(unknown),Daniel Gutiérrez,(unknown),Andrew Lau,Matthew B. Francis	1
2	MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor 2017 ·Oncotarget ·Sean Caenepeel,Keegan S. Cooke,(unknown),Guo N. Huang,Lídia Robert,Blanca Homet Moreno,Giulia Parisi,Elaina Cajulis,Richard Kendall,Pedro J. Beltran,Antoni Ribas,Angela Coxon,Paul E. Hughes	33
3	In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models 2016 ·Molecular Cancer Therapeutics ·Paul E. Hughes,Karen Rex,Sean Caenepeel,Yajing Yang,Yihong Zhang,Martin A. Broome,Hue T. Kha,Teresa L. Burgess,Benny Amore,Paula Kaplan‐Lefko,Jodi Moriguchi,Jonathan Werner,Michael A. Damore,D. N. Baker,Deborah M. Choquette,Jean-Christophe Harmange,Robert Radinsky,Richard Kendall,Isabelle Dussault,Angela Coxon	44
4	The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents 2015 ·Molecular Cancer Therapeutics ·Jude Canon,Tao Osgood,Steven H. Olson,Anne Y. Saiki,(unknown),Dongyin Yu,John Eksterowicz,Qiuping Ye,Lixia Jin,Ada Chen,Jing Zhou,David Cordover,Stephen A. Kaufman,Richard Kendall,Jonathan D. Oliner,Angela Coxon,Robert Radinsky	116
5	Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability 2014 ·ACS Medicinal Chemistry Letters ·Paul E. Harrington,Kaustav Biswas,David J. Malwitz,Andrew S. Tasker,Christopher Mohr,Kristin L. Andrews,(unknown),Richard Kendall,Holger Beckmann,Peter Jaeckel,(unknown),Jennifer R. Allen,J. Russell Lipford	74
6	IGF1R blockade with ganitumab results in systemic effects on the GH–IGF axis in mice 2014 ·Journal of Endocrinology ·Gordon Moody,Pedro J. Beltran,Petia Mitchell,Elaina Cajulis,(unknown),David Hwang,Richard Kendall,Robert Radinsky,Pinchas Cohen,Frank J. Calzone	19
7	AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues 2014 ·Journal of Translational Medicine ·Gloria Juan,Tammy L. Bush,(unknown),Raffi Manoukian,Grace Chung,(unknown),Stephen J. Zoog,Richard Kendall,Robert Radinsky,Robert D. Loberg,Greg Friberg,Marc Payton	10
8	Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method 2014 ·Laboratory Investigation ·Marc Payton,(unknown),(unknown),Dongyin Yu,Raffi Manoukian,Grace Chung,Nancy R. Zhang,Ji-Rong Sun,Paula Kaplan‐Lefko,Sheila Scully,Gwyneth Van,Robert Radinsky,Richard Kendall,Jonathan D. Oliner,Angela Coxon	5
9	AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models 2013 ·Molecular Cancer Therapeutics ·Tammy L. Bush,Marc Payton,Scott Heller,Grace Chung,Kelly Hanestad,James B. Rottman,Robert D. Loberg,Gregory Friberg,Richard Kendall,Douglas C. Saffran,Robert Radinsky	44
10	Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab 2013 ·PLoS ONE ·Frank J. Calzone,Elaina Cajulis,(unknown),(unknown),Petia Mitchell,John Lu,Ching Chen,Jilin Sun,Robert Radinsky,Richard Kendall,Pedro J. Beltran	28
11	Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth 2010 ·Molecular Cancer Therapeutics ·Josette Carnahan,Pedro J. Beltran,Carol Babij,Quynh‐Thu Le,Mark J. Rose,Steven Vonderfecht,Joseph L. Kim,Adrian L. Smith,Karthik Nagapudi,Martin A. Broome,Manory Fernando,Hue T. Kha,Brian Belmontes,Robert Radinsky,Richard Kendall,Teresa L. Burgess	58
12	Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor 2010 ·Molecular Cancer Therapeutics ·Teresa L. Burgess,Jan Sun,Susanne Meyer,Trace S. Tsuruda,Jilin Sun,Gary Elliott,Qing Chen,Mitsuru Haniu,(unknown),Todd Juan,Ke Zhang,Angela Coxon,Richard Kendall	68
13	AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells 2009 ·Molecular Cancer Therapeutics ·Pedro J. Beltran,Petia Mitchell,(unknown),Elaina Cajulis,John Lu,Brian Belmontes,Joanne Ho,(unknown),Min Zhu,Steven Vonderfecht,Renato Baserga,Richard Kendall,Robert Radinsky,Frank J. Calzone	113
14	The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase 2004 ·Bioorganic & Medicinal Chemistry Letters ·Mark T. Bilodeau,(unknown),Georgia B. McGaughey,Kathleen Coll,(unknown),William F. Hoffman,Randall W. Hungate,Richard Kendall,Rosemary C. McFall,Keith Rickert,Ruth Z. Rutledge,Kenneth A. Thomas	27
15	Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22 2003 ·Clinical Cancer Research ·Josette Carnahan,Paul Wang,Richard Kendall,Ching Chen,Sylvia Hu,T. Boone,Todd Juan,Jane Talvenheimo,Silvia Montestruque,Jilin Sun,Gary Elliott,John Thomas,John Ferbas,Brent Kern,Robert Briddell,John P. Leonard,Alessandra Cesano	5
16	Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR 2003 ·Bioorganic & Medicinal Chemistry Letters ·Mark T. Bilodeau,(unknown),(unknown),(unknown),Kathleen Coll,William R. Huckle,Randall W. Hungate,Richard Kendall,Rosemary C. McFall,Xianzhi Mao,Ruth Z. Rutledge,Kenneth A. Thomas	13
17	Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors 2002 ·Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley,William F. Hoffman,Robert S. Rubino,Randall W. Hungate,Andrew J. Tebben,Ruth Z. Rutledge,Rosemary C. McFall,William R. Huckle,Richard Kendall,Kathleen Coll,Kenneth A. Thomas	105
18	Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues 1999 ·Journal of Biological Chemistry ·Richard Kendall,Ruth Z. Rutledge,Xianzhi Mao,Andrew J. Tebben,Randall W. Hungate,Kenneth A. Thomas	99
19	Implementation of a Virtual Enterprise for Reservoir Management Applications 1997 ·Proceedings of SPE Annual Technical Conference and Exhibition ·(unknown),Mark Murphy,Richard Kendall,(unknown),(unknown),(unknown),(unknown),Jason Weiss,(unknown)	1
20	Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRbreakdown → 1996 ·Biochemical and Biophysical Research Communications ·Richard Kendall,Guan Wang,Kenneth A. Thomas	597

About Richard Kendall

Richard Kendall is a scholar working on Hepatology, Cancer Research and Oncology, having authored 43 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (9 papers), Microtubule and mitosis dynamics (8 papers) and Cancer Treatment and Pharmacology (8 papers). The work is most often cited by research in Hepatology (313 citations), Cancer Research (476 citations) and Oncology (837 citations). Richard Kendall has collaborated with scholars based in United States, Sweden and Germany. Frequent co-authors include Kenneth A. Thomas, Guan Wang, Robert Radinsky, Xianzhi Mao, Angela Coxon, William R. Huckle, Teresa L. Burgess, Randall W. Hungate, Ruth Z. Rutledge and Karen Rex. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact